KRAS and NRAS mutations, which also activate downstream pathways related to cell survival, are less frequent than KIT mutations and may be associated with more aggressive phenotypes, although their role in the development of TGCT and clinical outcomes is still unclear. The gene discussed is KRAS; the disease is testicular germ cell tumor.